Original articleA Comparison of Long-term Intraocular Pressure Fluctuation in Patients Treated With Bimatoprost or Latanoprost
Section snippets
Methods
The analysis was performed on data collected in a previously reported randomized, prospective, multicenter, investigator-masked clinical trial comparing bimatoprost and latanoprost.15 Inclusion criteria for the study were patients with either glaucoma or OHT and baseline IOP (8 am) following appropriate washout between 22 mm Hg and 34 mm Hg in each eye. There were no significant differences between treatment groups in patient age, gender, race, iris color, diagnosis, or need for washout.
Baseline Intraocular Pressure
Baseline analyses included 266 eyes in the bimatoprost group and 272 eyes in the latanoprost group. The untreated baseline mean IOP at each hour for eyes in the bimatoprost and latanoprost groups is shown in the Table. At 8 am and 4 pm, the two groups were comparable with respect to mean IOP. At 12 pm, mean IOP was higher in the bimatoprost group compared with the latanoprost group. Short-term daily fluctuation in IOP at untreated baseline was similar between the two groups (Table).
Intraocular Pressure Fluctuation During Treatment
The number
Discussion
Elevated IOP remains the predominant risk factor for glaucoma. While the EMGT analysis revealed only mean IOP as a factor leading to progression, a number of recent studies have suggested that fluctuation in IOP may also serve as an independent risk factor for glaucomatous VF progression.1, 2, 7, 10, 11 The recent study by Hong and associates7 demonstrates that in patients with relatively low and well-controlled IOP, IOP fluctuation may play a role in leading to progression. Within this
References (26)
- et al.
Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study
Ophthalmology
(2004) - et al.
Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial
Ophthalmology
(2007) - et al.
Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma
Ophthalmology
(2008) - et al.
Impact of intraocular pressure regulation on visual fields in open-angle glaucoma
Ophthalmology
(1999) - et al.
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
Am J Ophthalmol
(2003) - et al.
Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost
Surv Ophthalmol
(2001) - et al.
A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study
Am J Ophthalmol
(2003) - et al.
24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial
Surv Ophthalmol
(2004) - et al.
Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients
Ophthalmology
(2005) - et al.
Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination
Ophthalmology
(2003)
Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United StatesThe United States Latanoprost Study Group
Ophthalmology
Association between intraocular pressure variation and glaucoma progression: data from a United States chart review
Am J Ophthalmol
Intercurrent factors associated with the development of open-angle glaucoma in the European Glaucoma Prevention Study
Am J Ophthalmol
Cited by (7)
Control of intraocular pressure and fluctuation with fixed-combination brimonidinetimolol versus brimonidine or timolol monotherapy
2011, American Journal of OphthalmologyCitation Excerpt :Konstas and associates have reported studies evaluating the 24-hour range of IOP during treatment with a variety of IOP-lowering medications.25–29 Analyses of data from previously reported studies have further compared the effectiveness of various prostaglandin analogs in controlling short-term or long-term IOP fluctuation.30,31 As IOP fluctuation may have an important effect on VF progression and patient outcomes, we recommend that analyses of data from additional comparative studies be performed to evaluate IOP fluctuation as well as mean IOP levels with available IOP-lowering medications.
Assessing the Efficacy of Latanoprost vs Timolol Using an Alternate Efficacy Parameter: The Intervisit Intraocular Pressure Range
2009, American Journal of OphthalmologyCitation Excerpt :The impact of such differences on progression awaits further research. The role of long-term IOP fluctuation in progression of glaucoma and ocular hypertension remains unclear, at least in part because of differences among studies in their designs, patient populations, and durations of follow-up.6–8,19,21–24 Long-term IOP fluctuation measured by the intervisit range has a biologically reasonable relationship to glaucomatous progression in that homeostatic mechanisms may be disrupted, creating intermittent unevenness on the optic nerve.12
Impact of myopia on the association of long-term intraocular pressure fluctuation with the rate of progression in normal-tension glaucoma
2021, British Journal of OphthalmologyCost-offset analysis: Bimatoprost versus other prostaglandin analogues in open-angle glaucoma
2011, American Journal of Managed Care